Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis Bi-26
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis Bi-26 is a **live biotherapeutic probiotic strain** consisting of *Bifidobacterium longum* subspecies *infantis* Bi-26, originally isolated from infant feces and developed as a nutritional microbiome intervention for infants. Its intended mechanism is colonization of the infant gut and **metabolism of human milk oligosaccharides**, including 2'-fucosyllactose, thereby promoting a bifidobacteria-dominant microbiota, production of beneficial microbial metabolites, and downstream support of gut barrier, immune maturation, and growth. The strain has been studied mainly in infant nutrition and microbiome-development settings, including underweight or malnourished infants and preclinical piglet models, and is typically formulated as a lyophilized oral powder resuspended in breast milk or water.
- Brand names
- Bi-26Bi26Bi 26
- Other names
- Bifidobacterium longum subspecies infantis Bi-26Bifidobacterium longum subsp. infantis Bi-26Bi-26Bi26Bi 26
Beyond the preview
Go deeper on Bifidobacterium infantis Bi-26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis Bi-26.